• Revenue: Reported a decrease to $13.0 million in Q4 and $51.1 million for the full year, compared to the previous year.

• Net Loss: Increased net loss to $28.0 million in Q4 and $93.8 million for the full year.

• Research and Development Expenses: R&D expenses rose to $35.3 million in Q4 and $133.6 million for the full year.

• General and Administrative Expenses: G&A expenses slightly increased to $8.6 million in Q4 and $33.8 million for the full year.

• Liquidity Position: Cash, cash equivalents, and marketable securities totaled $223.6 million as of December 31, 2023.

• Operational Milestones: Advanced clinical programs and received a $40 million milestone payment from Roche.

• Collaboration Termination: Roche to terminate collaboration agreement with Repare in May 2024.

• Warning! GuruFocus has detected 4 Warning Signs with RPTX.

On February 28, 2024, Repare Therapeutics Inc (NASDAQ:RPTX) released its 8-K filing, detailing the financial results for the fourth quarter and the full year ended December 31, 2023. The precision oncology company, which specializes in developing synthetic lethality-based therapies for cancer patients, has reported a year of significant clinical progress despite facing financial headwinds.

Financial Performance and Strategic Highlights

Repare Therapeutics Inc (NASDAQ:RPTX) reported a decrease in revenue from collaboration agreements, which stood at $13.0 million for the fourth quarter and $51.1 million for the full year, compared to $18.2 million and $131.8 million for the same periods in 2022, respectively. This decline was attributed to lower deferred revenue recognized from the Roche collaboration and the BMS collaboration. Despite this, the company received a $40 million milestone payment from Roche, which contributed to its cash reserves of $223.6 million as of the end of 2023.

The company's net R&D expenses increased to $35.3 million in the fourth quarter and $133.6 million for the full year, primarily due to higher personnel-related costs and direct external costs related to the progress of their lunresertib clinical program. G&A expenses also saw a slight increase to $8.6 million in the fourth quarter and $33.8 million for the full year, mainly due to higher personnel-related costs.

Repare Therapeutics Inc (NASDAQ:RPTX) reported a net loss of $28.0 million, or $0.67 per share, for the fourth quarter, and a net loss of $93.8 million, or $2.23 per share, for the full year. This compares to a net loss of $31.7 million, or $0.75 per share, and $29.0 million, or $0.69 per share, for the same periods in 2022, respectively.